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Abstract Human complement regulatory (also called inhibi-
tory) proteins control misdirected attack of complement against
autologous cells. Trypanosome and schistosome parasites which
survive in the host vascular system also possess regulators of
human complement. We have shown Sh-TOR, a protein with
three predicted transmembrane domains, located on the Schis-
tosoma parasite surface, to be a novel complement regulatory
receptor. The N-terminal extracellular domain, Sh-TOR-ed1,
binds the complement protein C2 from human serum and
specifically interacts with the C2a fragment. As a result Sh-
TOR-ed1 pre-incubated with C2 inhibits classical pathway (CP)-
mediated haemolysis of sheep erythrocytes in a dose-dependent
manner. In CP-mediated complement activation, C2 normally
binds to C4b to form the CP C3 convertase and Sh-TOR-ed1 has
short regions of sequence identity with a segment of human C4b.
We propose the more appropriate name for TOR of CRIT
(complement C2 receptor inhibitory trispanning).
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1. Introduction
Complement (C) activation can be regulated by a number
of membrane-associated or soluble (secreted) C regulatory
proteins. Activation of the classical pathway (CP) is regulated
by the blocking of the CP C3 convertase, C4b2a. This action
is mediated by regulators of complement activation (RCA) [1]
or complement control proteins (CCPs), which essentially in-
hibit the activation of C on the surface of host cells. In the
£uid phase these include factor I, [2] and C4b binding protein
[3,4]. The membrane-bound RCAs (mRCA) [5] control con-
vertase on host cells and these include decay-accelerating fac-
tor, DAF (CD55) [6] and complement receptor type I (CR1)
or C3b/C4b receptor (CD35) [7]. DAF [8,9] and CR1 [10^12]
inhibit the binding of C2 to C4b and promote the dissociation
of C2a from C4b in the C3 convertase. Membrane cofactor
protein, MCP (CD46), and CR1 also promote the catabolism
of C4b by the plasma serine protease, factor I [13,14]. The
ampli¢cation steps of complement (C3 and C5 convertases)
are thus targeted by three membrane-bound regulators, MCP,
DAF and CR1. Such mRCAs are more highly expressed in
certain carcinoma cells and continuous cell lines [15^17] and it
is believed that this overexpression protects such cells from
complement-dependent cytotoxicity (CDC).
Homologues of human C regulators have been found in
other species. In particular, the surfaces of certain human
parasites which spend at least a part of their life cycle in the
host vascular system have such proteins, possibly to protect
them against host CDC. Schistosomes, for example, inhibit C
activation by adsorbing host DAF from erythrocytes [18]
whilst trypanosomes express CD59 and DAF homologues
with decay-accelerating activity for both classical and alterna-
tive pathway convertases [19] or for the alternative pathway
only [20].
This paper describes Sh-TOR [21], which is found on the
surface of the Schistosoma parasite, as a receptor to which
human complement C2 can bind speci¢cally. This results in
the inhibition of the CP of C activation, probably by interfer-
ing with the formation of the C3 convertase, C4b2a. Receptor
a⁄nity chromatography with the Sh-TOR ligand binding re-
gion extracellular domain 1 (ed1) was used to isolate the li-
gand from normal human serum (NHS). This was shown by
N-terminal sequencing and Western blot analysis to be com-
plement C2. The C regulatory function of Sh-TOR is sug-
gested by a haemolytic assay in which the Sh-TOR-ed1 pep-
tide, which contains the C2 binding region, causes inhibition
of lysis.
2. Materials and methods
2.1. Antibodies
Horseradish peroxidase (HRP)-conjugated secondary antibodies
were obtained from Bio-Rad. The HRP-conjugated rabbit anti-goat
antibody was purchased from Sigma. Rabbit anti-Sh-TOR-ed1 was
described before [21]. Rabbit polyclonal anti-(human C2) and anti-
(human factor B) antibodies were produced in the MRC Immuno-
chemistry Unit by immunisation with puri¢ed proteins. The anti-C2
monoclonal antibody HYB50-5 [22] was a gift from Dr C. Koch,
State Serum Institute, Copenhagen.
2.2. Receptor a⁄nity chromatography
The Sh-TOR-ed1 peptide (NH2-MSPSLVSDTQKHERGSHEVKI-
KHFSPY-COOH) was coupled to epoxy-activated Sepharose 6B (3
mg/ml and 2 ml ¢nal gel volume) at pH 9. Excess active groups were
blocked with ethanolamine. After two successive washes in borate
bu¡er (pH 8) and acetate bu¡er (pH 4), the a⁄nity matrix was placed
in a column (5 cmU1 cm diameter) and equilibrated with phosphate-
bu¡ered saline (PBS) at 20‡C. Then 5 ml of human serum diluted with
one volume of PBS was passed through. The column was washed with
PBS until the A280 of the eluate was 6 0.005. Bound material was
eluted with 0.1 M glycine^HCl (pH 2.8). 1 ml fractions were collected,
neutralised with 50 Wl 1 M Tris^HCl (pH 8.5) and analysed by SDS^
PAGE.
2.3. SDS^PAGE and Western blotting
Protein assay by dye binding (Bio-Rad protein assay kit) was car-
ried out to ensure even loadings for SDS^PAGE, which together with
Western blot analysis of proteins was done as described previously
[21].
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2.4. Protein sequencing
Protein(s) obtained by ‘receptor a⁄nity chromatography’ were re-
solved by SDS^PAGE with 2 mM mercaptoacetic acid in the upper
electrode bu¡er, and transferred to ProBlott1 (Applied Biosystems).
The protein visible with Coomassie blue was subjected to N-terminal
sequencing.
2.5. Haemolytic assay
Inhibition of the CP of C activation was determined as follows.
Various concentrations of Sh-TOR-ed1 peptide in 50 Wl freshly
made DGVB2 [23] were pre-incubated with 100 Wl of NHS (diluted
1/40 in DGVB2) for 30 min at room temperature and added to 50 Wl
EA (sheep erythrocytes, 2U108/ml, coated with antibodies). The mix-
tures were incubated at 37‡C for 30 min and cells centrifuged. The
controls, both made up to 200 Wl with DGVB2 consisted of cells plus
50 Wl of the maximum concentration of peptide (10 WM) and cells plus
100 Wl of NHS (1/40 dilution). A 100% lysis control (lysed by water)
was also included. Per cent haemolysis was calculated from the A412 of
the supernatant [23].
A haemolytic assay in which C2 concentration was limiting was
performed similarly. Essentially the same concentrations of peptide
(in 50 Wl DGVB2) were pre-incubated with 2 Wg C2. This was then
added to 100 Wl of C2-de¢cient serum (Sigma) (diluted 1/80), before
adding 50 Wl of EA. After 1 h at 37‡C, haemolysis was determined by
haemoglobin release. C2 used in this assay was prepared by immu-
noa⁄nity chromatography (N. Wong, T.P. Hickling, A. Laich, B.
Mo¡att, MRC Immunochemistry Unit, unpublished).
3. Results
3.1. Identi¢cation of a ligand for Sh-TOR by a⁄nity
chromatography
Fig. 1 shows the membrane topology of Sh-TOR as pre-
dicted by computer analysis (PHDhtm) [24]. The surface ex-
posure of the N-terminal segment was con¢rmed by use of
anti-Sh-TOR-ed1 antibody in £uorescent microscopy of RBL-
2H3 cells transfected with Sh-TOR [21] and by showing that
none of the predicted six N-linked glycosylation sites in the
Sh-TOR-id2 region is utilised [21]. In the Schistosoma para-
site, Sh-TOR was located to the surface tegument of the adult
worm and is believed to be in contact with host blood plasma.
The protein has nine tyrosine residues in the predicted cyto-
plasmic domain, and was shown to be phosphorylated on ty-
rosine [21]. This, together with its predicted membrane top-
ology and predicted three transmembrane domains, meant
that it was probably a new orphan receptor for some protein
ligand in the host blood plasma. Sh-TOR has two extracellu-
lar and therefore putative ligand binding domains, extracellu-
lar domains 1 and 2 (ed1 and ed2). In order to identify a
possible ligand of the receptor, ed1 was used in a⁄nity chro-
matography to see whether it would selectively bind any hu-
man serum proteins.
NHS (5 ml) was passed through a column of epoxy-acti-
vated Sepharose 6B covalently coupled with the 27 amino acid
long Sh-TOR-ed1 peptide (which is highlighted in Fig. 1).
Fractions were collected from a low pH elution and 10 Wl
aliquots resolved by SDS^PAGE. As shown in Fig. 2, the
Coomassie-stained gel revealed three protein bands, of (ap-
proximate) molecular weights 94 kDa, 67 kDa and 30 kDa.
Protein sequencing of the 30 kDa band revealed the N-termi-
nal sequence: NH2-APSCPQNV. A search of the data base
resulted in the assignment of this sequence as human comple-
ment C2b (30 kDa) part of C2 which in fully glycosylated
form is 102 kDa. Puri¢ed C2 is highly susceptible to proteol-
ysis by plasma proteases yielding C2a and C2b [25]. In a
standard C2 puri¢cation method [26], protease inhibitors
would be included in the starting serum but the a⁄nity puri-
¢cation carried out here was at 25‡C and in the absence of
protease inhibitors. Immunoblotting with a polyclonal anti-C2
antibody speci¢cally recognised 67 kDa and 30 kDa bands
(Fig. 2, lane 2). The monoclonal antibody against C2a
strongly recognised the 67 kDa band, C2a. That both C2a
and C2b were identi¢ed on elution from the column suggested
that proteolysis probably occurred after binding of the intact
C2 to the Sh-TOR-ed1 a⁄nity column. When the mixture of
C2a and C2b was passed back through the column, after
washing, only C2a was speci¢cally retained by the ed1 column
and subsequently eluted (not shown).
Complement proteins C2 of the CP and factor B of the
alternative pathway show 39% identity at the amino acid level
[27]. Western blot analysis was also carried out using anti-
factor B antibodies. No positive interaction was found (not
shown).
3.2. Inhibition of classical pathway-mediated lysis of sheep
erythrocytes by Sh-TOR-ed1
To determine whether the interaction of C2 with Sh-TOR-
Fig. 1. Schematic representation showing predicted membrane topol-
ogy of Sh-TOR [21] including three predicted transmembrane (TM)
domains, cytoplasmic tail, and a predicted myristoylation site. The
extracellular domains (ed1 and ed2) are indicated. The ed1 region is
depicted by ¢lled circles, a peptide based on this sequence having
been used in a⁄nity puri¢cation of the C2 ligand from NHS. The
intracellular domains (id1 and id2) are also indicated.
Fig. 2. Identi¢cation of ligand for Sh-TOR by receptor a⁄nity chro-
matography using the immobilised ed1 putative ligand binding do-
main. Lane 1, Coomassie-stained SDS^PAGE of a low pH eluate
from a chromatography carried out on 5 ml of NHS. Lane 2 is a
Western blot of the same sample, probed with a polyclonal anti-C2.
Lane 3 is a Western blot as for lane 2 probed with a monoclonal
antibody HYB50-5 recognising C2a.
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ed1 could a¡ect the normal interaction of C2 with other C
proteins, the e¡ect of Sh-TOR-ed1 peptide on C-dependent
lysis of antibody-sensitised sheep erythrocytes was tested.
There was a dose-dependent inhibition of lysis, with inhibition
evident at 1033^1032 WM ed1. The maximum concentration of
Sh-TOR-ed1 peptide tested (V7 WM) gave approximately
30% inhibition of lysis (Fig. 3a).
As an additional con¢rmation that Sh-TOR-ed1 speci¢cally
binds to human complement C2, C2-de¢cient human serum
with enough C2 added to reconstitute haemolytic activity was
used in the same assay. Pre-incubation of Sh-TOR-ed1 pep-
tide with C2 before addition to the C2-de¢cient serum was
found to inhibit haemolytic activity, once more in a dose-de-
pendent manner (Fig. 3b), with a maximum 43% inhibition of
lysis.
These results suggest that Sh-TOR binds speci¢cally to hu-
man complement C2 and that it inhibits the CP of C activa-
tion, presumably by inhibiting the formation of the CP C3
convertase (C4b2a). No comparable inhibitor of C2 has been
described previously.
3.3. Amino acid sequence homology of Sh-TOR and Sm-TOR
with C4b
The function of C2 in the CP is mediated by its binding
with C4b but the region on C4b to which C2 binds has not yet
been identi¢ed. The TOR-ed1 sequences of trematodes (Sh-
TOR-ed1 and Schistosoma mansoni or Sm-TOR-ed1) were
compared with that of human C4b to look for any homology
which might be related to C2 binding. The result in Fig. 4
shows a similar region, in the L-chain of human C4b. Mouse
C4b sequence is also included for comparison because mouse
and human C2 are 76.2% identical (or 80.3% similar) at the
amino acid level. The Sh-TOR-ed1 sequence from residue Ser2
to Tyr27 and C4b L-chain from residue Ser225 to Tyr251 share
35% homology or 42% taking into account conservative ami-
no acid replacement.
4. Discussion
We have presented evidence that Sh-TOR encodes a func-
tional receptor. The main criterion, from this study, is its
a⁄nity for the human C2 protein. From previous work [21],
Sh-TOR was found to be recognised by an antibody raised
against the N-terminal, predicted extracellular domain, and to
be of an equivalent size to that predicted from the open read-
ing frame [21]. Sh-TOR, which is phosphorylated on tyrosine,
was found principally in the tegument of the Schistosoma
adult worm [21]. Having assigned to Sh-TOR the function
of receptor for C2, we postulate that it constitutes a novel
C regulator or inhibitor. If so, it presumably does not act
systemically, but rather acts at the interface between tegument
and plasma. Its e⁄ciency as an inhibitor would in this case
depend on both a⁄nity and its density (concentration) on the
tegument surface.
That Sh-TOR prevents the formation of the classical C3
convertase by preventing C2 from binding to C4b was sug-
gested in this work by showing that the 27 amino acid long
Sh-TOR-ed1 can bind C2 in an a⁄nity puri¢cation of human
C2 from NHS. This was con¢rmed by then using a soluble
form of Sh-TOR, in the form of the Sh-TOR-ed1 peptide, to
inhibit in a dose-dependent manner the haemolytic activity of
C2 from the CP of C activation. It appears likely that Sh-
TOR-ed1 competes with C4b for binding to C2.
That the inhibitory concentration of Sh-TOR-ed1 in hae-
molytic assays of about 10 WM (40-fold higher than the con-
centration of C2 in NHS) is not any lower may be due to
peptide sequestration by low a⁄nity interactions with other
plasma proteins or to an unusual conformational structure of
the ligand binding domain presented in the form of a synthetic
peptide. We would thus expect that if at least ed1 were pre-
sented in a more ‘native’ conformation, an inhibitory concen-
tration closer to the serum concentration of C2 would have
been obtained. At this stage it is not known what contribu-
tion, if any, ed2 may play in C2 binding to Sh-TOR. Besides
the extracellular loops being involved in the binding of C2 to
Sh-TOR, it is conceivable that certain amino acids within the
cavity formed by the three transmembrane K-helices may also
play a part. Further studies to reveal which particular residues
in ed1 are critical for C2 binding should now be possible. The
¢nding that only C2a bound and was subsequently eluted
when a mixture of C2a and C2b was applied to the Sh-
TOR-ed1 a⁄nity column, shows that Sh-TOR-ed1 binds spe-
ci¢cally the C2a region of C2.
Fig. 3. Inhibition of human C by Sh-TOR-ed1. a: E¡ect of increas-
ing Sh-TOR-ed1 peptide on the C-mediated killing of sensitised
sheep erythrocytes in the presence of NHS as a source of C. b: Ef-
fect of increasing Sh-TOR-ed1 peptide, pre-incubated with C2, on
haemolysis, in the presence of C2-de¢cient serum (Sigma).
Fig. 4. Sequence alignment between S-TOR-ed1 and C4b. Amino acid sequence alignment of the N-terminal ed1 regions of Schistosoma haema-
tobium-TOR and Schistosoma mansoni-TOR with a region from the L-chain of human and mouse C4b (numbering according to GenBank re-
lease P01028 and P01029 respectively) with which they show homology. Residues within dark grey boxes are identical and those within light
grey boxes are similar. A full stop indicates a gap introduced to make the alignment. A consensus sequence is also given.
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Human C4b binds C2 and although the C2 binding site on
C4b has not yet been identi¢ed, the two C4b binding sites on
C2 have been described. C2b, the domain which binds with
C4b initially, consists of three Sushi (SCR) repeats or CCP
repeats of 62, 57 and 55 amino acid residues, all three of
which constitute the Mg2-independent C4b binding site
[28,29]. After C1s cleaves C2 to release C2b, C2a remains
attached to C4b with a higher binding avidity. C2a is bound
via the MIDAS (metal ion-dependent adhesion site) which lies
within the VWFA domain of C2a [30,31]. In view of the C2
binding site on C4b not having been identi¢ed so far, it is
interesting that we report within the L-chain of C4b a region
homologous to the C2 binding ed1 domain of Sh-TOR.
As a result of the data presented, it seems appropriate to
rename Schistosoma trispanning orphan receptor (TOR) as S-
CRIT (complement C2 receptor inhibitory trispanning).
Structural studies to understand in detail the Sh-CRIT-ed1
interaction with C2 are now under way.
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